Erratum: Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)

K. Kalinsky; F. Hong; C. K. McCourt

doi:10.1001/jamaoncol.2021.5290

Erratum: Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)

K. Kalinsky, F. Hong, C. K. McCourt

Research output: Contribution to journal › Comment/debate

Abstract

Error in the Abstract: In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue,1 the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.

Original language	English
Pages (from-to)	1729
Number of pages	1
Journal	JAMA oncology
Volume	7
Issue number	11
DOIs	https://doi.org/10.1001/jamaoncol.2021.5290
State	Published - Nov 2021

Access to Document

10.1001/jamaoncol.2021.5290

Cite this

@article{a7420921c8c540619fe9949b797068c1,

title = "Erratum: Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)",

abstract = "Error in the Abstract: In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue,1 the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.",

author = "K. Kalinsky and F. Hong and McCourt, {C. K.}",

year = "2021",

month = nov,

doi = "10.1001/jamaoncol.2021.5290",

language = "English",

volume = "7",

pages = "1729",

journal = "JAMA Oncology",

issn = "2374-2437",

number = "11",

}

TY - JOUR

T1 - Erratum

T2 - Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)

AU - Kalinsky, K.

AU - Hong, F.

AU - McCourt, C. K.

PY - 2021/11

Y1 - 2021/11

N2 - Error in the Abstract: In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue,1 the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.

AB - Error in the Abstract: In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue,1 the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.

UR - http://www.scopus.com/inward/record.url?scp=85116476944&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2021.5290

DO - 10.1001/jamaoncol.2021.5290

M3 - Comment/debate

C2 - 34591077

AN - SCOPUS:85116476944

SN - 2374-2437

VL - 7

SP - 1729

JO - JAMA Oncology

JF - JAMA Oncology

IS - 11

ER -

Erratum: Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial (JAMA Oncol. (2021) 7:2 (271-278) DOI: 10.1001/jamaoncol.2020.6741)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this